Molecular targets of selenium in prostate cancer prevention (Review)

Rizky Abdulah1, Kenji Kobayashi, Chiho Yamazaki

  • 1Division of Pharmacology and Clinical Pharmacy, Faculty of Pharmacy, Universitas Padjadjaran, Jl. Raya Bandung Sumedang Km.21, Jatinangor 45363, Indonesia. abdulahrizky@gmail.com

Insights

Selenium shows promise in treating prostate cancer, inhibiting its development through various mechanisms. Further research supports its potential clinical use for this male cancer.

Area of Science:

  • Oncology
  • Nutritional Science
  • Molecular Biology

Background:

  • Prostate cancer is a significant cause of cancer-related mortality in men.
  • Clinical applications of the micronutrient selenium for prostate cancer are currently limited.
  • Emerging evidence suggests selenium's therapeutic potential in prostate cancer management.

Purpose of the Study:

  • To review current epidemiological and biomolecular research on selenium's role in prostate cancer.
  • To evaluate the prospects of selenium for future clinical application in prostate cancer treatment.

Main Methods:

  • Literature review of epidemiological studies.
  • Analysis of biomolecular research on selenium's mechanisms of action.
  • Assessment of clinical trial outcomes and future potential.

Main Results:

  • Selenium demonstrates inhibitory effects on prostate cancer through multiple biological pathways.
  • Existing clinical trial data, though limited, indicates positive outcomes with selenium use.
  • Selenium appears beneficial in controlling the progression of prostate cancer.

Conclusions:

  • Selenium is a promising micronutrient for prostate cancer intervention.
  • Further investigation into selenium's efficacy and safety in clinical settings is warranted.
  • Selenium holds potential for integration into future prostate cancer treatment strategies.

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Cancer Prevention02:59

Cancer Prevention

Several factors can increase the risk of cancer in an individual. About 50% of cancer cases can be prevented by adopting a healthy lifestyle, regular exercise, eating healthy, and following a modest cancer prevention diet. Epidemiological studies have consistently shown that populations with vegetable and fruit-rich diets have reduced the incidence of cancer. On the other hand, populations who have a diet rich in animal fat, red meat, junk food, or high calories are predisposed to cancer.
Some...
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...